Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.09 USD | +3.00% | +3.68% | +94.90% |
Business Summary
Number of employees: 37
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Novel Bispecific Antibodies
100.0
%
| 20 | 100.0 % | 7 | 100.0 % | -64.09% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Netherlands
100.0
%
| 20 | 100.0 % | 7 | 100.0 % | -64.09% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 56 | 19-05-31 | |
Fred M. Powell
DFI | Director of Finance/CFO | 63 | 22-10-31 |
Chief Tech/Sci/R&D Officer | - | 21-11-08 | |
Chief Tech/Sci/R&D Officer | 50 | 16-12-31 | |
Chief Tech/Sci/R&D Officer | 59 | 23-02-05 | |
Chief Tech/Sci/R&D Officer | 60 | 18-04-30 | |
Robin Hume
LAW | General Counsel | - | 23-05-14 |
Human Resources Officer | - | 21-11-08 | |
Amy Garabedian
LAW | General Counsel | - | 21-07-26 |
Peter Ros
PRN | Corporate Officer/Principal | 52 | 19-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 56 | 19-05-31 | |
Karen Wilson
BRD | Director/Board Member | 61 | 21-03-31 |
James Noble
BRD | Director/Board Member | 65 | 22-06-14 |
Peter Kiener
BRD | Director/Board Member | 72 | 22-12-31 |
Jay Backstrom
BRD | Director/Board Member | 69 | 22-06-14 |
Kapil Dhingra
CHM | Chairman | 64 | 21-02-21 |
Mary Wadlinger
BRD | Director/Board Member | 64 | 22-12-31 |
Christy Oliger
BRD | Director/Board Member | 54 | 23-03-08 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 26,289,087 | 18,738,315 ( 71.28 %) | 0 | 71.28 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+94.90% | 78.87M | |
+22.75% | 46.4B | |
-1.88% | 41.75B | |
+48.83% | 41.37B | |
-3.42% | 29.71B | |
+10.25% | 26.01B | |
-18.90% | 19.52B | |
+28.28% | 12.43B | |
+0.10% | 12.18B | |
-0.66% | 12.13B |
- Stock Market
- Equities
- LVTX Stock
- Company LAVA Therapeutics N.V.